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Abstract
Background: Institutional review boards (IRBs) distinguish health care quality improvement (QI) and health care
quality improvement research (QIR) based primarily on the rigor of the methods used and the purported generalizability
of the knowledge gained. Neither of these criteria holds up upon scrutiny. Rather, this apparently false dichotomy may
foster under-protection of participants in QI projects and over-protection of participants within QIR.
Discussion: Minimal risk projects should entail minimal oversight including waivers for informed consent for both QI
and QIR projects. Minimizing the burdens of conducting QIR, while ensuring minimal safeguards for QI projects, is
needed to restore this imbalance in oversight. Potentially, such ethical oversight could be provided by the integration
of Institutional Review Boards and Clinical Ethical Committees, using a more integrated and streamlined approach such
as a two-step process involving a screening review, followed by a review by committee trained in QIR. Standards for
such ethical review and training in these standards, coupled with rapid review cycles, could facilitate an appropriate
level of oversight within the context of creating and sustaining learning health care systems.
Summary: We argue that QI and QIR are not reliably distinguishable. We advocate for approaches that improve
protections for QI participants while minimizing over-protection for participants in QIR through reasonable ethical
oversight that aligns risk to participants in both QI and QIR with the needs of a learning health care system.
Keywords: Ethics, Research, Research subjects, Ethics, committees research, Health services research, Quality
improvement, Quality improvement research, Ethics, clinical, Informed consent, Waiver of informed consent, Learning
health care systems
Background
In a provocative pair of articles, Kass et al. and Faden
et al. argue that the research-treatment distinction is no
longer tenable, and propose new ethical principles for
guiding both research and treatment in the context of a
learning health care system [1, 2]. Their proposed princi-
ples regard the failure to use information gathered from
the point of care for research and learning as unethical.
However, their papers leave open the question of how to
begin such reform. Actionable next steps under current
regulations are uncertain.
Our experience with many research and quality im-
provement research projects has prompted us to reflect
on these complex issues and propose concrete next steps
that might be adopted under the current ethical regula-
tions for research. We focus on the interface between
quality improvement research (QIR) and quality im-
provement (QI). We argue that QIR and QI are indistin-
guishable; that they are sufficiently distinct from other
types of clinical research that they warrant their own
distinct processes and committees for ethical oversight
and that the level of oversight should balance risk to
participants with an ethical imperative to improve care.
Discussion
Existing guidelines distinguish QI and research
The United States Department of Health and Human
Services (DHHS) regulates biomedical and behavioral
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research ethics in the United States under the Common
Rule. It has remained largely unchanged since 1991 and
reform appears stalled [3]. Both the Common Rule and
World Health Organization (WHO) guidelines attempt to
distinguish QI and research [4]. This is understandable
based on concerns that placing QI under The Common
Rule could hinder processes designed to improve patient
care and ultimately reduce patient risk [5].
QI and QIR are not reliably distinguishable
The Common Rule, WHO guidelines, and consensus state-
ments have sought to distinguish research and QI based on
the rigor of methods (internal validity) and generalizability
(external validity) of the findings [4–6]. On close inspec-
tion, these criteria alone do not hold up.
Rigor of methods
Traditional research methods, and the methodological
rigor they represent, enhance the internal validity of the
findings whether considered research or not. That is, they
improve confidence that the findings are valid for the pop-
ulation(s) under scrutiny. However, high internal validity is
not unique to research including quality improvement re-
search (QIR). Rather, use of rigorous methods is based on
two often competing goals. The first goal is minimizing
type I error (essentially a false positive finding or inferring
an effect exists when none actually exists) as well as type II
(a false negative finding or inferring no effect exists when
one actually exists). The second goal is feasibility of the
methods. Feasibility issues include technical, methodo-
logical (e.g. types of design) operational (e.g. effects on
workflow), costs, and acceptability to patients, providers,
administrators, and communities. The desire to reduce in-
valid inference, whether due to type I or II errors, applies
to both QI and QIR. For example, a large, national health
plan conducting QI might have a strong desire to minimize
type I error through use of highly rigorous methods, in-
cluding randomization, while also minimizing type II error,
through sufficiently large sample sizes, before rolling it out
to all plan members. As with QIR, QI must balance strong
methods against feasibility. The competing goals of getting
the correct answer with practical constraints do not clearly
distinguish QI and QIR.
The risks associated with invalid findings, whether QI or
QIR, have important ethical implications. Both entail costs
and potential burden to participants, and the possibility of
risks to future patients. Use of less rigorous study designs,
i.e. those associated with a higher risk of confounding, may
result in spurious findings and invalid inferences. Further-
more, this means that research and/or health care re-
sources are potentially squandered and that participants
are exposed to unnecessary risks and burdens (however
minimal) with the possibility of little or no benefit, or even
the possibility of harm, particularly where understudied
subgroups experience paradoxical effects.
Generalizability of findings
The second major criterion −generalizability (external
validity)- is also problematic in distinguishing QI from
QIR. First, QI and QIR (and other pragmatic research)
often involve use of “real world” settings and partici-
pants. In contrast, traditional clinical research is often
much less generalizable, as it is often conducted in highly
specialized academic settings, and with highly selected
(homogeneous) patient populations that exclude many co-
morbid conditions [7, 8]. A traditional randomized con-
trolled trial with a long list of highly selective eligibility
criteria may yield findings that are less generalizable than
a QI intervention conducted with patients with fewer or
no eligibility restrictions, particularly those that exclude
patients with multiple comorbidity. Traditional random-
ized controlled trials are often intended to generate
generalizable knowledge of a different sort, i.e. scientific
principles, mechanisms, processes or theory. Nonetheless,
in terms of extrapolation of findings regarding the inter-
vention itself, these trials often have poor generalizability
[9]. In contrast, QIR trials often examine patient popula-
tions similar to those used in QI projects. In both cases,
the selection of participants is based on the level of
generalizability, i.e. to other patients in a system or more
broadly to similar participants.
The second challenge to generalizability as a distin-
guishing feature is that generalizability represents a broad
continuum without clear lines of demarcation. Most QI
findings are intended to generalize beyond the partici-
pants, health care delivery systems and practice settings
involved in the QI project. A large health plan or large
hospital system might conduct a quality improvement
project within several geographic regions with the hopes
of generalizing the findings nationally. Depending on the
context and unique features of the organization, the find-
ings may or may not be generalizable to other plans and
practice settings. Similarly, few QIR projects involve suffi-
ciently large or diverse population of patients, of clinicians
and of practices to ensure widespread generalizability and
replicability.
The generalizability conundrum is not remedied by
resorting to the stated intent of the project. Asking the
project leaders whether they intend to generalize their
findings (i.e. knowledge gleaned) beyond the participants
is misleading. QI projects invariably involve some degree
of generalizability, even if it is limited to the population
served by the institution that generates the findings from a
sample of observed patients. This may include extrapola-
tion of findings to concurrent non-participating patients
or to future patients. In contrast to QI leaders, QIR leaders
often overestimate the generalizability of their findings and
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minimize threats to external validity [10]. In addition,
stated intent may be distorted to reflect the desire of expe-
diency based on avoiding IRB review or based on journal
requirements for IRB review. In sum, generalizability is a
continuum without clear cut-offs that reliably distinguish
QI for QIR.
Other criteria
Other proposed criteria for distinguishing QI from re-
search similarly do not reliably distinguish QI and QIR.
Casarett et al. suggest that a project should be deemed
research if a majority of patients involved are not ex-
pected to benefit [11]. These criteria are more helpful in
distinguishing QI from traditional clinical research than
from QIR, which potentially entails as much direct bene-
fit to participating patients as QI projects. Given the ab-
sence of standards for implementing QI, there is no a
priori reason to believe that expected benefit would be
greater with QI than with QIR.
Whether a project imposes additional risks and burden
to improve generalizability represents a second criterion
proposed by Casarett et al. [11] It, too, fails the test.
Pragmatic research, including QIR, strives to avoid un-
due burden on participants [8]. Other proposed criteria,
including source of funding, plans for publication and
dissemination, and involvement of researchers in the pro-
ject [12], are arbitrary and not grounded in ethical princi-
ples relevant to protection of participants, and may be
subject to change over time as a project evolves and as
new questions are raised based on information gleaned
from the project.
Balancing competing ethical principles
If QI and QIR are not readily distinguishable, then what
are the implications for ethical oversight? How should
ethical oversight be balanced with the need to create con-
tinuous learning health care systems? When is informed
consent by patients necessary and under what conditions
are informed consent required from clinicians and other
staff? With the increased attention to “pragmatic research”
using electronic health records, under what conditions is a
waiver of informed consent necessary and reasonable? In
the remainder of this paper, we address these questions.
Risk to participants versus the imperative to improve care
The level of scrutiny should balance the risk to partici-
pants with the need to expedite care improvement in-
cluding an ethical imperative to learn quickly [13, 14].
This balancing of competing ethical principles should be
the primary task, rather than seeking to resolve an arbi-
trary distinction between QI and QIR. Currently, most
large QI projects appear to undergo some level of re-
view, particularly with regards to participant risk and
confidentiality of data [15]. However, the quality of this
review may be variable and typically ill defined [15].
Length of IRB reviews among the same QI and QIR pro-
jects vary widely [16–18]. Standardization of oversight
for QI and QIR is needed. This approach would help
prevent future mishaps, e.g. suspensions of national QIR
projects [19].
Ethical review considerations
Unlike current QI reviews (which are often internal)
[15], ethical oversight reviews including those for QI
should be independent and should reflect bioethical and
methodological expertise, and perspectives from adminis-
trators, clinicians and patients. Ethical review should con-
sider soundness of the methods, including whether the
methods are sufficiently rigorous to meet the goals and
scope of the project and minimize invalid inferences. An
ethical review for QI and QIR would not preclude use of
rapid cycle or Plan-Do-Study-Act (PDSA) approaches that
are fundamental to learning health care systems, but
would help to ensure appropriate use of resources, as well
as protection of patient privacy and safety.
Ethical oversight can be provided using current insti-
tutional oversight committees with some modifications.
This would mean creation of a separate committee to re-
view QI/QIR projects. Provided that current ethical
guidelines for research, e.g. ‘The Common Rule” are
followed, and that reasonable criteria for minimal risk
criteria are applied, QI and QIR could be reviewed by
the same committee. Burden could be further reduced
using a two-step process.
Two-step process
A two-step process minimizes delays and the burdens
for review for minimal risk projects while ensuring docu-
mentation of minimal review. The first step would involve
submission of a succinct, e.g. one page document that
summarizes key ethical considerations. An Alberta, Canada
Consensus Initiative has developed ethical criteria for con-
sideration for QI projects [20]. A children’s hospital in
Australia has taken a similar approach to QI [21]. These
criteria, which are also relevant to QIR, include usefulness
of knowledge, methods, fair appropriate selection of partic-
ipants (or data), steps to maximize benefit and minimize
risk, respect for rights of individuals, communities and
populations, and informed consent. These criteria are simi-
lar to those used to determine IRB exemption.
The QI/QIR document would be reviewed by a person
designated by the oversight committee (first step). This
reviewer would either approve the project or refer the
project for further committee review (second step). Op-
timally, this would occur within a few days and not take
longer than a week for a determination. This two-step
process is similar to “expedited reviews.” Potential differ-
ences would include a shorter application, shorter turn-
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around times, and review by members with QI/QIR eth-
ics expertise.
Periodic auditing of documents and decisions by a sec-
ond member of the oversight committee could help to
standardize approval, referral decisions and documenta-
tion, while ensuring quality oversight through an audit
trail. The first quick step minimizes the risk of projects
being considered “exempt” from full review in the ab-
sence of auditable documentation of minimal, independ-
ent review.
Integration of clinical and research ethics oversight
Who should provide ethical oversight of QI/QIR? QI/
QIR are sufficiently distinct from other types of clinical
research that they warrant their own dedicated oversight
committee. In theory, an oversight committee could res-
ide within an existing IRB structure, i.e. as a QI/QIR IRB
committee. Alternatively and regulations permitting, it
could represent a new organizational structure. Expertise
on this oversight committee would optimally include pa-
tients, including previous participants in QI/QIR, and
experts in conducting QI and QIR, in addition to ex-
perts in ethical oversight. Improved integration of ethical
oversight within the context of a learning health care
system could be achieved by expanding committee
membership beyond members with expertise in applying
ethical principles to groups, to include members with
expertise in applying ethical principles to individual pa-
tients. This could be accomplished by inviting members
from Clinical Ethical Committees (CECs) to join the QI/
QIR ethical oversight committee. CECs provide clinical
consultations not only to clinicians, staff, patients, and
families, but also establish and oversee institutional guide-
lines and procedures that involve ethical concerns [22].
CECs are experienced in weighing risks and benefits dur-
ing clinical care and thus could potentially offer a valuable
perspective in applying ethical principles relevant to a
learning health care system in the context of QI/QIR.
This integration of CECs into ethical oversight of QI/
QIR would minimize the silos between research and
treatment and facilitate cross-fertilization of expertise
and perspectives. An integrated committee might pro-
vide more informed oversight of QI/QIR than IRBs with
traditional membership.
Training of QI/QIR ethical oversight committees
Even among traditional IRBs, there is wide variation in
IRB’s composition, efficiency, perspectives, training and
requirements [23]. Members in a QI/QIR oversight com-
mittee will require relevant training. Ideally, training
would be provided conjointly with other members in
order establish shared understanding of review criteria.
Most patients have not been trained in ethical oversight,
and are less familiar with QI/QIR ethical issues than non-
patients. However, even many experts in QI have not been
formally trained in ethical principles. Members of CECs
will need to learn to apply ethical principles in the context
of QI and QIR. Traditional IRB members will need to
learn how to weigh protections to patients in the context
of an imperative to continuously improve health care.
Training would be similar to that adopted by A Project
Ethics Community Consensus Initiative (ARECCI) for re-
view of quality improvement projects [20]. The training
would include selected readings followed by facilitated
group discussion. Key topics would include: 1) Purposes
and appropriate methods of QI/QIR; 2) Specific examples
of ethical concerns; 4) Issues related to consent and condi-
tions required for a waiver of informed consent; 5) Process
for balancing competing ethical concerns, including po-
tential benefits, risks, and burdens to potential partici-
pants, i.e. patients, staff and/or administration) and to the
health care system and patients at large. Most notably,
such training would aim to establish shared understanding
among committee members regarding how to balance
competing ethical concerns in ways that would facilitate
rather than hinder the development of learning health
care systems. Shared understanding and common goals
are critical to ensuring an efficient, timely and fair review.
For example, the committee would decide under what
conditions the ethical benefit of ensuring that project find-
ings are more generalizable (by granting a waiver of in-
formed consent) trumps the need for obtaining individual
consent from all participants. Similarly, the committee
would decide when more rigorous methods are required
to avoid erroneous inferences followed by roll-out of a
flawed quality improvement intervention.
This new committee would also establish a roadmap for
integrating committee self-assessment, user feedback, and
review into the operations. This change in paradigm will
not occur overnight. It will require an iterative process in-
volving action, reflection, and revision by the committee.
It will require careful attention to process over time in-
cluding timeliness of reviews, useful revisions to projects,
and input from multiple perspectives and stakeholders in-
cluding patients. Most importantly, it will require open-
ness to new thinking, new ways for ethical review, and
engagement of clinicians and patients in oversight.
Informed consent
Reluctance to subject QI to ethical oversight reflects a
legitimate concern that such ethical oversight could
undermine creation of learning health care systems. [6]
This includes concerns about problematic delays in
implementing QI, but also concerns about the potential
for requiring informed consent for participants in QI
projects, and the likelihood of introducing selection bias
by those who opt-in versus opt-out [24]. These are valid
concerns; there is an ethical obligation on the part of
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patients, staff, and clinicians to contribute towards a learn-
ing health care system, with benefits that accrue not only
to the patients, but also to society as a whole [2].
Informed consent is intended to protect participants
from exposure to additional risks posed by ‘research’ they
have not agreed to that goes beyond the standard of clin-
ical care, while respecting their autonomy and preferences
[25]. This process is analogous to informed consent for
patient care. In both cases, informed consent balances
benefits, risks and practical considerations. For minimal-
risk procedures, such as commonly ordered blood tests
during patient care, informed consent from patients is nei-
ther required nor routinely obtained beyond general con-
sent for treatment. Obtaining informed consent for every
single test could result in greater harm (through delays
and wasted resources) than benefit. Formal informed con-
sent is reserved for procedures where the stakes, both
risks and benefits, are greater e.g. surgical procedures or
medications that carry significant side effects [26]. How-
ever, when the procedure entails appreciate risk such as
surgical treatment, informed consent specific to the pro-
cedure is obtained from the patient. This same balance be-
tween benefits, risks and practical considerations is
relevant to both QI and QIR.
Under current USA Federal Regulations informed par-
ticipant consent may be waived if the research in question
poses “no more than minimal risk to the participants,” and
if failing to obtain informed consent “will not adversely
affect the rights and welfare of the subject,” and if “the re-
search could not practicably be carried out,” and if “when-
ever appropriate, the subjects will be provided with
additional pertinent information after participation.” [27]
These considerations are applicable to virtually all QI and
much of QIR though the ultimate determination lies in the
oversight committee's assessment of competing risks and
benefits. For example, it may not be feasible to conduct a
pragmatic trial of outreach for patients past due for cancer
screening using traditional informed consent. The primary
target population for these efforts would be systematically
excluded by a requirement for informed consent, because
this population is the most difficult to reach due to changes
in address, phone numbers and infrequent office visits
[28, 29]. Thus, results would not be generalizable to the
population of interest. In this case, we agree with Faden et
al. that a waiver of informed consent is necessary [30].
Individual informed consent is often not feasible for
cluster randomized controlled trials and comparative ef-
fectiveness research (CER) studies where the organization
is the primary target of the intervention [31, 32]. Requir-
ing individual informed consent from all participants in-
cluding all patients render these trials obsolete with
accompanying loss of new knowledge. Obtaining waivers
for individual informed consent in cluster randomized tri-
als, requires consideration of feasibility, knowledge gained,
and the balance of benefits and risks to participants
[31, 33, 34].
Informing new patients upon their enrollment in care
regarding potential QI/QIR and obtaining acknowledge-
ment, i.e. universal consent, represents another way to
inform patients when opt-out might not be feasible. This
approach could strengthen requests for waivers of in-
formed in the presence of favorable benefit-risk to partici-
pants while offering patients with the choice to obtain
care at other organizations. For higher risk projects, opt-
out approaches could be used to recruit (and subsequently
consent) patients. This could include notifying the patient
by mail or electronically that a project has begun and that
they have the right to opt-out by calling a number [35].
This passive approach to informed consent may minimize
response bias that occurs with active, opt-in consent [36].
Conclusion
QI and QIR are not reliably distinguishable, but rather
comprise a continuum of activities. We recommend the
development and institutionalization of new approaches
that build on existing structures, such as a two-step
process, to facilitate ethical review of QI/QIR and pro-
mote learning health care systems within a rapidly chan-
ging health care environment. We recommend creating
expert ethical oversight committees to review both QI
and QIR. Such committees can operate under many
existing regulations regarding minimal risk research and
waivers of informed consent. The ultimate goal of this
approach is to balance the protection of the rights of
participants in QI/QIR with the ethical imperative to im-
prove care as rapidly as possible by building a healthcare
system that continuously learns from its data.
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